Building the Path to 3D-Printed Organs, Cellbricks Raises €10M for Biofabricated Tissue Implants
Berlin‑based Cellbricks Therapeutics secured €10 million (≈$11 million) in funding, including a €7 million seed round and over €3 million of non‑dilutive capital, to advance its light‑based biofabrication platform. The company aims to commercialise vascularised human tissue implants for complex wound healing and breast reconstruction as a stepping stone toward fully functional organ printing. Its in‑house expertise spans cells, biomaterials, printers, software and clinical translation, giving it a unique competitive edge. Partnerships with large pharma are being pursued to fund preclinical studies and accelerate market entry.
Genes From Giant Viruses Help Polar Algae Survive Frigid Waters and Harsh Sunlight
Researchers have found that giant viruses contribute roughly five percent of the genome in polar algae, the highest proportion recorded for any host. In the unicellular green algae Chlamydomonas, more than 400 virus‑derived regions encode over 25,000 genes, including ice‑binding...
Maze Meets Own Expectations in Phase 2 Kidney Disease Trial in the Same Arena as Vertex
Maze Therapeutics reported that its Phase 2 trial of the genetic kidney disease candidate MZ‑001 achieved its primary efficacy and safety goals, showing a roughly 30% slowdown in eGFR decline versus placebo. The double‑blind study enrolled 150 patients with autosomal dominant...
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
WuXi Biologics reported record 2025 results, with revenue up 16.7% and IFRS gross profit climbing 30.9%, lifting its gross margin to 46%. The growth was driven by expanding research, development and manufacturing contracts and tighter cost control across its global...
Metformin’s Hidden Brain Pathway Revealed After 60 Years
Researchers at Baylor College of Medicine have identified a brain‑based pathway that underlies metformin’s glucose‑lowering effect. The study shows that metformin suppresses the Rap1 protein in the ventromedial hypothalamus, a region critical for whole‑body glucose regulation. Mice lacking hypothalamic Rap1...
How GLP-1 Agonists Affect Gene Expression and Promote Pancreatic Health
Researchers at the Salk Institute identified the protein Med14 as the molecular bridge that links GLP‑1 agonist drugs to broad genomic responses that enhance pancreatic beta‑cell health. The team showed that phosphorylation of Med14 is essential for activating gene programs...
The United Laboratories and Novo Nordisk Report P-II Trial Data on UBT251 in Chinese Patients with Type 2 Diabetes
Novo Nordisk and United Laboratories reported Phase‑II data for the GLP‑1 agonist UBT251 in 211 Chinese patients with type‑2 diabetes. Over 24 weeks, UBT251 achieved a 2.16 % HbA1c reduction, outperforming semaglutide’s 1.77 % and placebo’s 0.66 % from a baseline of 8.12 %....
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
Gilead announced a $2.1 billion acquisition of Ouro Medicines and its T‑cell engager OM336, planning to split the deal with long‑time partner Galapagos. Johnson & Johnson and Protagonist Therapeutics secured FDA approval for Icotyde, an IL‑23 receptor blocker that becomes Protagonist’s...
Basecamp Research Unveils Trillion Gene Atlas to Boost Longevity Drug Discovery
Basecamp Research has launched the Trillion Gene Atlas, a platform that will collect and model genetic information from more than 100 million species, expanding known evolutionary diversity by roughly 100‑fold. The initiative aims to give AI models a vastly broader biological...
Merck Nears $6B All‑Cash Deal for Terns Pharma to Boost Oncology Portfolio
Merck & Co. is in advanced talks to acquire Terns Pharmaceuticals in an all‑cash transaction valued at about $6 billion. The deal would add a promising rare‑cancer therapy to Merck’s portfolio and could be announced as early as Wednesday.
Insufficient Source Data to Report on Hope Medicine's Phase III Trial
The requested story about Hope Medicine initiating a Phase III trial of a monoclonal antibody for endometriosis cannot be produced because none of the provided source material contains information on this development.
Magnetic Silk‑Iron Nanoparticles Offer Precise Drug Delivery to Inaccessible Tissues
A multinational research team has created magnetic silk‑iron nanocomposite particles that can be steered with external magnetic fields to deliver therapeutics directly to otherwise inaccessible tissues. The breakthrough promises higher efficacy and lower side‑effects for treatments ranging from cancer to...
Pfizer and Valneva's Lyme Vaccine Shows 73.2% Efficacy in Late‑Stage Trial
Pfizer and French biotech Valneva announced that their experimental Lyme disease vaccine, PF-07307405, achieved 73.2% efficacy in a Phase III trial, marking the most advanced effort to bring a U.S. Lyme vaccine to market despite missing its primary statistical benchmark. The...
Genomic Mapping of E. Coli Capsules Identifies High-Risk Types for Vaccines
A genomic survey of over 18,000 *Escherichia coli* genomes has mapped 90 capsular K‑loci, revealing that five capsule types (K1, K5, K52, K2, K14) cause more than half of bloodstream and urinary‑tract infections in Europe. The study links these high‑risk...
World-First Portable Multi-Pathogen CRISPR Test Seeks to Improve STI Diagnostics
Researchers at Australia’s Peter Doherty Institute have created a portable, CRISPR‑based diagnostic that simultaneously detects syphilis, HSV, chlamydia and gonorrhea in under an hour. The assay also identifies a key antibiotic‑resistance gene in gonorrhea, delivering 97‑100% accuracy compared with laboratory...
MSD and Quotient Collaborate on IBD Drug Targets
Merck (MSD) has entered a multi‑year research partnership with Quotient Therapeutics to uncover new drug targets for inflammatory bowel disease using Quotient’s somatic genomics platform. The deal provides Quotient with $20 million upfront and up to $2.2 billion in regulatory, development and...
STAT+: How an Outsider Crept Into Eli Lilly’s Top Ranks — and Plans to Drive Its Business Forward
Jacob Van Naarden, formerly COO of Loxo Oncology, joined Eli Lilly after its $8 billion cash acquisition of Loxo in 2018. He now serves as president of Lilly Oncology and head of business development, overseeing the company’s dealmaking and pipeline expansion. The purchase...
Ionis’ Zilganersen Receives US FDA Priority Review for Alexander Disease
Ionis Pharmaceuticals received FDA acceptance of its new drug application for zilganersen and a priority‑review designation for treating Alexander disease, with a PDUFA target action date of September 22, 2026. The Phase III trial enrolled 54 patients aged 1.5 to 53...
A Class Action Suits Moves RICO From Mobsters to Medicine
In this episode, attorney Harrison James explains how the Racketeer Influenced and Corrupt Organizations Act (RICO), originally aimed at organized crime, is being used in a landmark civil class action against Takeda Pharmaceuticals and Eli Lilly over the diabetes drug Actos....
Cybin Inc (HELP) Reports Positive Phase 2 Anxiety Study Data
Cybin Inc. announced topline results from a Phase 2 trial of its anxiety drug candidate HLP004, showing a 10‑point reduction on a standard anxiety rating scale. The study involved 36 patients already on antidepressants, and the benefit persisted for at least...
Trace Unites ALS Teams Behind a Target That Could Broaden Treatment Access
Trace Neuroscience, launched Nov 2024, is developing an antisense drug, TRCN‑1023, to restore UNC13A protein function in ALS patients. The target emerged from parallel discoveries at UCL and Stanford, and the company plans intrathecal delivery and biomarker‑guided trials. Leveraging lessons...
As Antibiotics Fail, a New Treatment Targets the Host, Not the Bacteria
Researchers at Trinity College Dublin have demonstrated that a single dose of interferon‑gamma can “train” human macrophages to more effectively kill drug‑resistant bacteria such as MRSA and Mycobacterium tuberculosis. The IFN‑γ‑trained cells undergo epigenetic reprogramming, rely on glutamine metabolism, and...
D+Q Senolytic Linked to Brain Demyelination, Prompting Safety Concerns
The recent study showing D+Q causes demyelination in brain cells leads to more questions than it answers: (I only read the abstract cause paper new & paywalled.) D+Q has been used a lot in mice & humans. Why hasn't this been noticed...
This Tiny Implant, Smaller than a Grain of Salt, Can Read Your Brain
Cornell researchers have unveiled the microscale optoelectronic tetherless electrode (MOTE), a neural implant barely larger than a grain of salt. The 300 µm‑by‑70 µm device wirelessly transmits brain‑wave data via infrared light and has demonstrated chronic operation in awake mice for more...
Cancer Drug Can Treat Drug-Resistant Herpes, Too
Researchers at the University of Illinois Chicago have repurposed the FDA‑approved cancer drug doxorubicin to combat drug‑resistant herpes simplex virus type 1 (HSV‑1). Using their AI‑driven platform HerpDock, they identified doxorubicin’s ability to block the PI3K‑AKT‑mTOR pathway that the virus exploits,...
Lyme Disease Isn’t a Bioweapon, Says Immunology Researcher
Since Lyme Disease is suddenly getting more attention than usual: Hi! I’m a researcher and scientist getting my PhD in Immunology, Infection and Epidemiology. I’ve been studying tick feeding and Lyme Disease for over 5 years now looking for an anti-tick...
Novo
$NVO triple G drug at 2.16 A1c reduction at only week 24 vs a lower 1.9 A1c reduction at a longer 40 weeks for the max dose of the $LLY triple G. But Novo has no pipeline…? 🤷🏻♂️ https://t.co/CFcnGZGMqt
Remote Robotic Stroke Surgery Triumphs in Panama, Paving Way for Global Tele‑Neurointervention
A neurosurgeon in Santiago performed a remote robotic thrombectomy on a stroke patient at The Panama Clinic, restoring cerebral blood flow within minutes. The breakthrough, part of XCath’s Operation Robo Angel study, demonstrates how AI‑enabled robotics can overcome geographic barriers...
Hybrid PandaOmics‑Lobster Platform Accelerates Disease Target Discovery
PandaOmics and Lobster hybrid for novel target discovery and disease hypothesis research. @steipete will have serious impact on human life
CRBIOTECH's 2025 Impact Projected to Surge Significantly
📈 The projected 2025 impact of Current Research in Biotechnology is notably higher 🔗https://t.co/HTlbLhpaRc 🌐 #CRBIOTECH #Research #Science https://t.co/DOBMVCJUgC
Lenz Therapeutics Misses Q4 Forecast, Shares Slide 11.2%
Lenz Therapeutics reported a Q4 loss of $1.16 per share on $1.6 million in revenue, far below analysts' expectations of a $0.90 loss on $3.1 million. The miss sent the biotech’s shares down 11.2% as investors reacted to higher SG&A costs and...
AL-S Pharma Tests How Far SOD1 Biology Extends Into Sporadic ALS
The article outlines BioCentury’s cookie policy, detailing the categories of cookies used on its website—strictly necessary, functional, marketing, advertising, and analytics. Each type is described in terms of purpose, activation status, and impact on user experience. The policy emphasizes that...
Penn Engineers Unveil aroLNPs Cutting Liver Delivery Tenfold While Boosting Lymph‑Node Targeting
University of Pennsylvania bioengineers have created a redesigned lipid nanoparticle, aroLNP, that delivers at least ten‑fold less mRNA to the liver while preserving lymph‑node uptake. The breakthrough could lower the dose needed for effective vaccination and expand mRNA therapeutics.
Seeking Enzymes that Decolorize Anthocyanins Like Carotenoid Cleavers
Are there enzymes that cleave anthocyanins into colorless bits? I know there are carotenoid cleavage enzymes that can bite various parts of the saturated chain, but never heard of anthocyaninases... https://t.co/rUHXDWkWvc
Towards Intelligent and Miniaturized Drug Delivery Devices
Intelligent and miniaturized drug delivery devices (IMDDDs) combine biotechnology, AI, electronics, and novel materials to provide precise, programmable drug release inside the body. These platforms integrate real-time sensing with adaptive control, enabling dose adjustments based on biomarkers such as glucose...
U.S. FDA Approves Label Update to Accelerate Thaw Time for ADSTILADRIN® (Nadofaragene Firadenovec-Vncg)
The U.S. FDA has approved a label update for Ferring Pharmaceuticals' ADSTILADRIN® (nadofaragene firadenovec‑vncg) that permits an accelerated water‑bath thawing process completed in roughly 25 minutes. The therapy, the only FDA‑approved non‑replicating intravesical gene‑therapy for high‑risk BCG‑unresponsive non‑muscle invasive bladder...
Doctors for America Raises PDUFA, CNPV, Bayesian, Supply Chain Concerns With Lawmakers
Doctors for America met with bipartisan lawmakers to flag several regulatory concerns at the FDA. The group warned that “America First” provisions in the upcoming PDUFA negotiations could increase user fees and hinder drug access, while the agency’s reliance on...
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Absci Corporation announced that its AI‑designed antibody ABS‑201 has been dosed in the first three single‑ascending‑dose cohorts of the Phase 1/2a HEADLINE trial, showing favorable safety and early hair‑growth signals in human ex vivo studies. The company also unveiled Origin‑1, a generative‑AI...
Gilead to Pay $1.68 B for Ouro Medicines, Securing Antibody Platform for Autoimmune Diseases
Gilead Sciences announced a definitive agreement to acquire privately held Ouro Medicines for $1.675 billion in cash, with up to $500 million in milestone payments. The deal gives Gilead exclusive rights to CM336 (OM336), a T‑cell‑engaging antibody aimed at autoimmune disorders, and...
BMS’ Sotyktu Receives FDA Expansion in Psoriatic Arthritis
Bristol Myers Squibb received FDA approval expanding Sotyktu (deucravacitinib) to treat adults with active psoriatic arthritis, making it the first oral selective TYK2 inhibitor for this indication. The label extension is backed by the POETYK PsA-1 and PsA-2 trials, where...
Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript
Karyopharm Therapeutics announced top‑line data from its Phase III SENTRY trial, which evaluated selinexor combined with ruxolitinib in patients with myelofibrosis. The company reported that the regimen met its primary efficacy endpoints and demonstrated a manageable safety profile. Alongside the clinical...
New Off-the-Shelf Conduit for CABG Shows Promise in First-in-Human Study
Vascudyne’s acellular tissue‑engineered vessel with external support (ATEV‑ESS) demonstrated early promise as an off‑the‑shelf conduit in a first‑in‑human study. Three patients with multivessel coronary disease received the device; two implants remained patent at 12 months with no thrombus or major...
BioAge Labs Provides Business Updates
BioAge Labs reported full‑year 2025 results, highlighting positive Phase 1 data for its oral NLRP3 inhibitor BGE‑102, which achieved up to 86% reduction in hsCRP and strong suppression of IL‑1β, IL‑6, and fibrinogen. The company announced a Phase 2a cardiovascular risk trial...
How Pharma Supply Chains Can Brace for FDA’s 12-Digit NDC Standard
The FDA issued a final rule on March 5, 2026 establishing a uniform 12‑digit National Drug Code (NDC) that will replace the current variable 10‑digit format, with an effective date of March 7, 2033 and a seven‑year preparation window followed by a three‑year transition...
MaRS Impact Health Returns to Showcase Canada’s Next Big Healthcare Breakthroughs
MaRS Impact Health will convene more than 1,000 biotech, digital‑health and medical‑device innovators in Toronto on April 23, showcasing Canada’s push to define a "middle‑power" role as the global healthcare market fragments. The summit highlights rare‑disease breakthroughs, including mRNA vaccine...
CSA Announces $3.6M Opportunity for Life Sciences Research on the ISS
The Canadian Space Agency (CSA) has launched a $3.6 million CAD (≈ $2.6 million USD) Announcement of Opportunity to fund health and life‑sciences research on the International Space Station. Up to $900,000 CAD (≈ $660,000 USD) per project will be awarded to Canadian teams...
Safety Similar Across Advanced Crohn’s Disease Therapies
Researchers analyzed real‑world claims data from 12,245 Crohn’s disease patients treated between 2016 and 2022 to compare safety outcomes across five advanced therapies, including TNF antagonists, vedolizumab, ustekinumab, risankizumab, and upadacitinib. Incidence rates for serious infections, major adverse cardiovascular events,...
Patience Wins: Wait for Maintenance Data, Not Hype
$ABVX degen traders dumping the stock on a CNBC article saying exactly what I’ve been saying since the trial hit back in July, and what was already blatantly obvious from the earnings release yesterday. WAITING FOR MAINTENANCE DATA is...
Kintor’s KX-826 Meets Phase III Endpoints in Alopecia
Kintor Therapeutics announced that its oral JAK inhibitor KX-826 successfully met both primary and key secondary endpoints in a pivotal Phase III trial for alopecia areata. The double‑blind study enrolled 620 patients and showed statistically significant hair regrowth compared with...